- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 362467, 8 pages
Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
11st Department of Oncology, Faculty of Medicine, Comenius University, Spitalska 24, 813 72 Bratislava, Slovakia
2Department of Clinical Oncology, St. Elizabeth Cancer Institute, Heydukova 10, 812 50 Bratislava, Slovakia
Received 16 April 2013; Accepted 7 May 2013
Academic Editors: G. C. Fraizer, H.-W. Lo, G. Metro, and G. Schiavon
Copyright © 2013 Katarina Sevcikova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001.
- E. Tzahar, H. Waterman, X. Chen et al., “A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor,” Molecular and Cellular Biology, vol. 16, no. 10, pp. 5276–5287, 1996.
- J. A. Zell, W. Y. Tsang, T. H. Taylor, R. S. Mehta, and H. Anton-Culver, “Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry,” Breast Cancer Research, vol. 11, no. 1, article R9, 2009.
- J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi, “The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine,” Oncologist, vol. 14, no. 4, pp. 320–368, 2009.
- I. Rubin and Y. Yarden, “The basic biology of HER2,” Annals of Oncology, vol. 12, supplement 1, pp. S3–S8, 2001.
- H. D. Bear, “Indications for neoadjuvant chemotherapy for breast cancer,” Seminars in Oncology, vol. 25, no. 2, pp. 3–12, 1998.
- G. N. Hortobagyi, G. R. Blumenschein, W. Spanos et al., “Multimodal treatment of locoregionally advanced breast cancer,” Cancer, vol. 51, no. 5, pp. 763–768, 1983.
- G. N. Hortobagyi, F. C. Ames, A. U. Buzdar et al., “Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy,” Cancer, vol. 62, no. 12, pp. 2507–2516, 1988.
- G. N. Hortobagyi, “Comprehensive management of locally advanced breast cancer,” Cancer, vol. 66, no. 6, pp. 1387–1391, 1990.
- B. Fisher, J. Bryant, N. Wolmark et al., “Effect of preoperative chemotherapy on the outcome of women with operable breast cancer,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2672–2685, 1998.
- N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher, “Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18,” Journal of the National Cancer Institute, Monographs, no. 30, pp. 96–102, 2001.
- H. D. Bear, S. Anderson, A. Brown et al., “The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4165–4174, 2003.
- J. A. van der Hage, C. J. H. van de Velde, J. P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau, “Preoperative chemotherapy in primary operable breast cancer: results from the european organization for research and treatment of cancer trial 10902,” Journal of Clinical Oncology, vol. 19, no. 22, pp. 4224–4237, 2001.
- J. S. Mieog, J. A. van der Hage, and C. J. van de Velde, “Preoperative chemotherapy for women with operable breast cancer,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD005002, 2007.
- H. M. Kuerer, L. A. Newman, T. L. Smith et al., “Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol. 17, no. 2, pp. 460–469, 1999.
- S. V. S. Deo, M. Bhutani, N. K. Shukla, V. Raina, G. K. Rath, and J. Purkayasth, “Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 MO),” Journal of Surgical Oncology, vol. 84, no. 4, pp. 192–197, 2003.
- M. Kaufmann, G. von minckwitz, H. D. Bear et al., “Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006,” Annals of Oncology, vol. 18, no. 12, pp. 1927–1934, 2007.
- M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga, “Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells,” Cancer Research, vol. 61, no. 12, pp. 4744–4749, 2001.
- J. Baselga, J. Albanell, M. A. Molina, and J. Arribas, “Mechanism of action of trastuzumab and scientific update,” Seminars in Oncology, vol. 28, no. 5, supplement 16, pp. 4–11, 2001.
- N. L. Spector and K. L. Blackwell, “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5838–5847, 2009.
- W. Xia, R. J. Mullin, B. R. Keith et al., “Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways,” Oncogene, vol. 21, no. 41, pp. 6255–6263, 2002.
- R. Ghosh, A. Narasanna, S. E. Wang et al., “Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers,” Cancer Research, vol. 71, no. 5, pp. 1871–1882, 2011.
- D. N. Amin, N. Sergina, D. Ahuja et al., “Resiliency and vulnerability in the HER2-HER3 tumorigenic driver,” Science Translational Medicine, vol. 2, no. 16, Article ID 16ra7, 2010.
- J. Baselga and S. M. Swain, “Novel anticancer targets: revisiting HER2 and discovering HER3,” Nature Reviews Cancer, vol. 9, no. 7, pp. 463–475, 2009.
- D. Graus-Porta, R. R. Beerli, J. M. Daly, and N. E. Hynes, “ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling,” EMBO Journal, vol. 16, no. 7, pp. 1647–1655, 1997.
- S. T. Lee-Hoeflich, L. Crocker, E. Yao et al., “A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy,” Cancer Research, vol. 68, no. 14, pp. 5878–5887, 2008.
- M. C. Franklin, K. D. Carey, F. F. Vajdos, D. J. Leahy, A. M. de Vos, and M. X. Sliwkowski, “Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex,” Cancer Cell, vol. 5, no. 4, pp. 317–328, 2004.
- J. B. Hughes, C. Berger, M. S. Rødland, M. Hasmann, E. Stang, and I. H. Madshus, “Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization,” Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 1885–1892, 2009.
- A. Citri, K. B. Skaria, and Y. Yarden, “The deaf and the dumb: the biology of ErbB-2 and ErbB-3,” Experimental Cell Research, vol. 284, no. 1, pp. 54–65, 2003.
- G. Von Minckwitz, S. Loibl, and M. Untch, “What is the current standard of care for antiHER2 neoadjuvant therapy in breast cancer?” Oncology, vol. 26, no. 1, pp. 20–26, 2012.
- A. U. Buzdar, N. K. Ibrahim, D. Francis et al., “Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3676–3685, 2005.
- A. U. Buzdar, V. Valero, N. K. Ibrahim et al., “Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen,” Clinical Cancer Research, vol. 13, no. 1, pp. 228–233, 2007.
- L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort,” The Lancet, vol. 375, no. 9712, pp. 377–384, 2010.
- G. von Minckwitz, M. Rezai, S. Loibl et al., “Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2015–2023, 2010.
- M. Untch, M. Rezai, S. Loibl et al., “Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2024–2031, 2010.
- M. Untch, A. P. Fasching, E. G. Konecny, et al., “Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial,” Journal of Clinical Oncology, vol. 29, no. 25, pp. 3351–3357, 2011.
- J. Baselga, I. Bradbury, H. Eidtmann et al., “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial,” The Lancet, vol. 379, no. 9816, pp. 633–640, 2012.
- M. Untch, S. Loibl, J. Bischoff et al., “Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial,” The Lancet Oncology, vol. 13, no. 2, pp. 135–144, 2012.
- V. Guarneri, A. Frassoldati, A. Bottini et al., “Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1989–1995, 2012.
- L. Gianni, T. Pienkowski, Y. H. Im, et al., “Abstract S3-2: neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (“NeoSphere”),” Cancer Research, vol. 70, no. 24, supplement 2, 2010.
- A. Schneeweiss, S. Chia, T. Hickish, et al., “Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA),” Cancer Research, vol. 71, supplement 24, article 112s, 2011.
- V. Guarneri, K. Broglio, S. W. Kau et al., “Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1037–1044, 2006.
- G. von Minckwitz, M. Kaufmann, S. Kümmel, et al., “Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracyclinetaxane +/- trastuzumab containing chemotherapy,” Cancer Research, vol. 69, no. 2, supplement 1, 2009.
- G. von Minckwitz, M. Kaufmann, S. Kuemmel, et al., “Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis,” Journal of Clinical Oncology, vol. 29, abstract 1028, 2011.
- M. F. Rimawi, L. S. Wiechmann, Y. C. Wang et al., “Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts,” Clinical Cancer Research, vol. 17, no. 6, pp. 1351–1361, 2011.
- G. Bianchini, A. Prat, M. Pickl, et al., “Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: gene expression analysis,” Journal of Clinical Oncology, vol. 29, abstract 529, 2011.
- B. Dave, I. Migliaccio, M. C. Gutierrez et al., “Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2—overexpressing locally advanced breast cancers,” Journal of Clinical Oncology, vol. 29, no. 2, pp. 166–173, 2011.
- K. Berns, H. M. Horlings, B. T. Hennessy et al., “A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer,” Cancer Cell, vol. 12, no. 4, pp. 395–402, 2007.
- Y. Nagata, K. H. Lan, X. Zhou et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,” Cancer Cell, vol. 6, no. 2, pp. 117–127, 2004.
- I. Witzel, S. Loibl, G. von Minckwitz et al., “Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial,” Breast Cancer Research and Treatment, vol. 123, no. 2, pp. 437–445, 2010.
- I. Witzel, S. Loibl, G. von Minckwitz et al., “Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab—a translational project in the neoadjuvant GeparQuinto trial,” The British Journal of Cancer, vol. 107, no. 6, pp. 956–960, 2012.
- E. J. Jung, L. Santarpia, J. Kim et al., “Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients,” Cancer, vol. 118, no. 10, pp. 2603–2614, 2012.
- K. Tamura, C. Shimizu, T. Hojo et al., “FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer,” Annals of Oncology, vol. 22, no. 6, pp. 1302–1307, 2011.
- F. J. Esteva, J. Wang, F. Lin et al., “CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer,” Breast Cancer Research, vol. 9, no. 6, article R87, 2007.
- F. A. Holmes, Y. M. Nagarwala, V. A. Espina, et al., “Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy,” Journal of Clinical Oncology, vol. 29, abstract 506, 2011.
- S. Loibl, J. M. Bruey, G. von Minckwitz, et al., “Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study,” Journal of Clinical Oncology, vol. 29, abstract 530, 2011.
- J. Huober, S. Loibl, M. Untch, et al., “New molecular biomarkers for resistance to trastuzumab-based in primary HER2 positive breast cancer—a translational investigation from the neoadjuvant GeparQuattro study,” Cancer Research, vol. 70, supplement 24, abstract PD02-06, 2010.
- T. M. Suter, M. Procter, D. J. van Veldhuisen et al., “Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3859–3865, 2007.
- E. Tan-Chiu, G. Yothers, E. Romond et al., “Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7811–7819, 2005.
- D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001.
- G. Bianchi, J. Albanell, W. Eiermann et al., “Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer,” Clinical Cancer Research, vol. 9, no. 16, pp. 5944–5951, 2003.
- M. Untch, M. Muscholl, S. Tjulandin et al., “First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1473–1480, 2010.
- A. Seidman, C. Hudis, M. K. Pierri et al., “Cardiac dysfunction in the trastuzumab clinical trials experience,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1215–1221, 2002.
- V. Guarneri, D. J. Lenihan, V. Valero et al., “Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson cancer center experience,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4107–4115, 2006.
- C. E. Geyer Jr., J. Bryant, G. Yothers, et al., “Update of cardiac dysfunction on NSABP B-31: a randomized trial of subsequential AC→paclitaxel versus AC→paclitaxel with trastuzumab,” Journal of Clinical Oncology, vol. 24, no. 23, supplement, A581, 2006.
- J. Staaf, M. Ringnér, J. Vallon-Christersson et al., “Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1813–1820, 2010.
- D. A. Yardley, E. Raefsky, R. Castillo et al., “Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer,” Clinical Breast Cancer, vol. 11, no. 5, pp. 297–305, 2011.